Mainz Biomed N.V. UNDERWRITING AGREEMENTUnderwriting Agreement • January 21st, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between Mainz Biomed N.V., a Dutch public company with limited liability (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereafter defined) as being subsidiaries or affiliates of the Company, the “Company”) on the one hand, and Boustead Securities, LLC (the “Underwriter”), on the other hand, pursuant to which the Underwriter shall serve as the underwriter for the Company in connection with the proposed offering (the “Offering”) by the Company of their Securities (as defined below) on a “Firm Commitment” basis.
TECHNOLOGY RIGHTS AGREEMENTTechnology Rights Agreement • January 21st, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • Quebec
BETWEEN: Socpra sciences santé et humaines s.e.c., operating under the name TransferTech Sherbrooke, a Limited Partnership duly incorporated pursuant to the Civil Code of Québec, having its head office at 35 Radisson Street, Office 200, Sherbrooke, (Quebec), Canada, J1L 1E2, acting and represented by its General Partner, Gestion Socpra sciences santé et humaines inc., a legal person duly constituted under the Business Corporations Act (Quebec), said General Partner being represented by its agent and mandatory Gestion socpra Inc, herein acting and represented by Michel Lambert, its President and CEO, duly authorized for the purposes hereof as he so declares by signing; hereinafter referred to as “TTS”
